compounding glp-1 enforcement news The availability of compounded drugs has become easier to obtain, which has doctors and the U.S. Food and Drug Administration sounding the alarm. https://www.wspa.com/news/national/compounded-glp-1-drugs-creating-concern-among-doctors-and-fda Feds warn telehealth companies about

Compounded medications such as those promoted in the Hims & Hers ad arent approved by the Food and Drug Administration

The choice between LR3 and DES is not either/orits about matching the compound to your training focus and biological response window. Duan, Frontiers in Endocrinology Conclusion: IGF-1 LR3 vs IGF-1 DES Final Takeaway Both IGF-1 LR3 and IGF-1 DES offer impressive muscle-building, fat-burning, and recovery-enhancing benefitsbut theyre built for different applications

The mechanism of AOD 9604 in subcutaneous adipose tissue Activation of fat breakdown (lipolysis) AOD 9604 promotes fat breakdown through the following pathways: Activation of the 3-AR signaling pathway: AOD 9604 binds to 3-AR on the adipocyte membrane, activates adenylic acid cyclase (AC), increases the intracellular cyclic adenosine monophosphate (cAMP) level, and thereby activates protein kinase A (PKA)

obviously each of these has very different business models (for example, DRI and CMG are almost completely company owned, while WING is almost exclusively franchised) and are at different places in their growth life cycle, so each deserves slightly (or massively!) different multiples and valuations, but, across the board, these multiples seem pretty rich even in a vacuum